Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC with Cisplatin and Doxorubicin in Recurrent Ovarian Cancer
NCT02475772Phase 1Completed
- Start
- Nov 2016
- Primary completion
- May 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cisplatin and doxorubicin in ovarian cancer and peritoneal carcinomatosis (PC). Primary endpoint: Adverse events according to CTCAE criteria at 12 weeks. Started Nov 2016; status: completed.
02
Drugs
cisplatindoxorubicin
03
Conditions
ovarian cancerperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT02475772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02475772.